Ftse Mib
35.394,23
-0,04%
DAX
18.650,02
-0,40%
S&P 500
5.297,10
-0,21%
NASDAQ
16.698,32
-0,26%
Bitcoin
66.211,39
1,49%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lumos Pharma Inc (LUMO) Lumos Pharma Inc (LUMO) Notizie

Lumos Pharma Inc

LUMO
2,63
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:01:30
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
15/5/202415:57EDGAR2Form 8-K - Current report
14/5/202422:15GLOBELumos Pharma Announces Positive End-of-Phase 2 Meeting with..
09/5/202420:51GLOBELumos Pharma to Report First Quarter 2024 Financial Results..
18/4/202422:05GLOBELumos Pharma Announces Abstracts Accepted for Presentation..
20/3/202413:00GLOBELumos Pharma Announces that the USPTO Has Granted Patent..
07/3/202422:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/3/202422:44EDGAR2Form 8-K - Current report
07/3/202422:01GLOBELumos Pharma Reports Full Year 2023 Financial Results and..
26/2/202415:00GLOBELumos Pharma to Report Full Year 2023 Financial Results and..
07/2/202423:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202422:02EDGAR2Form 144 - Report of proposed sale of securities
05/2/202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:05GLOBELumos Pharma to Participate in Oppenheimer’s 34th Annual..
11/1/202401:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/1/202422:34EDGAR2Form 8-K - Current report
04/1/202422:05GLOBELumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to..
29/11/202322:30EDGAR2Form SC 13D/A - General statement of acquisition of..
21/11/202322:15GLOBELumos Pharma to Host Virtual Key Opinion Leader Webinar to..
20/11/202322:05GLOBELumos Pharma Announces Participation in the Piper Sandler..
15/11/202322:38EDGAR2Form 8-K - Current report
08/11/202300:24DJNLumos Pharma Shares Than Double After Hormone Deficiency..
07/11/202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:42EDGAR2Form 8-K - Current report
07/11/202322:35GLOBELumos Pharma Reports Third Quarter 2023 Financial Results..
07/11/202322:08EDGAR2Form 8-K - Current report
07/11/202322:01GLOBELumos Pharma Announces Topline Data from Phase 2..
26/9/202322:34EDGAR2Form 8-K - Current report
26/9/202315:00GLOBELumos Pharma Announces New Data and Analysis of 15 Subjects..
14/9/202314:00GLOBELumos Pharma Announced Abstract Accepted for Oral..
07/9/202322:34GLOBELumos Pharma Announces Participation in Investor Conferences..
22/8/202315:00GLOBEIndependent Panel of Renowned Pediatric Endocrinologists to..
10/8/202315:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:36EDGAR2Form 8-K - Current report
09/8/202322:01GLOBELumos Pharma Reports Second Quarter 2023 Financial Results,..
03/8/202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202321:54EDGAR2Form 144 - Report of proposed sale of securities
26/7/202315:00GLOBELumos Pharma to Report Second Quarter 2023 Financial Results..
12/7/202314:00GLOBELumos Pharma to Participate in the Oppenheimer 2023 Montauk..
28/6/202322:26EDGAR2Form 8-K - Current report
28/6/202322:01GLOBELumos Pharma Announces Departure of Chief Medical Officer
21/6/202315:00GLOBELumos to Highlight New LUM-201 Data and Analysis Presented ..
31/5/202314:00GLOBELumos Pharma to Participate in the Upcoming 2023 BIO..
25/5/202314:00GLOBELumos Pharma Announces Abstracts Accepted for Oral..
22/5/202315:00GLOBELumos Pharma to Participate in World Orphan Drug Congress..
Apertura: Min: Max:
Chiusura: 2,63

La tua Cronologia

NASDAQ
LUMO
Lumos Pharma
UNSW3
APYETH
APY Governance Token
LSE
SDG7
X Sdg 7 Energy
NASDAQ
CDEV
Centennial Resource Deve...
LSE
IUMD
Usa Mmtm Usd-d
HITB
BANCABTC
Banca
NYSE
GIC
Global Industrial
USOTC
VFEAF
Vanguard Funds PLC FTSE ... (PK)
NASDAQ
TIBBD
KOSPI
007210
Byuksan
UNSW3
BSJETH
BASENJI
BOV
BBASV610
BBASV610 Ex:27,47
LSE
TO01
Natwest.m 24
GATE
BLURUSDT
Blur
HUOB
GSCETH
Global Social Chain
NASDAQ
OPESU
Opes Acquisition
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network